Intermediate dry age-related macular degeneration

Allegro successfully completed a Phase 2a trial of patients with intermediate dry AMD, the results of which were presented at different national and international congresses in 2019 and 2020. Allegro is preparing to initiate a Phase 3 clinical program in Q4 2020. Read more about completed Phase 2a studies on

Diabetic macular edema

Risuteganib met its primary endpoints in two Phase 2b trials. Allegro is currently evaluating next development steps. Read more about the completed Phase 2b studies. View study on

Dry eye disease

ALG-1007 demonstrated promising results in an ex-U.S. proof-of-concept clinical trial, in which it showed efficacy, a significant dose response curve, and that it was well-tolerated with no adverse events. A second and larger ex-U.S. Phase 2 clinical trial was successfully completed.